Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25.
Br J Haematol. 2014.
PMID: 24661044
Free PMC article.
Clinical Trial.
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A.
Mato AR, et al. Among authors: valentinetti m.
Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30.
Am J Hematol. 2015.
PMID: 25691474
Free article.
Clinical Trial.
Item in Clipboard
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.
Romaguera JE, et al. Among authors: valentinetti m.
Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.
Cancer. 2018.
PMID: 29723393
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite